Kwang Dong Pharmaceutical Co., Ltd.
KKRX:0092906,590.00
KRW
-40.00
(-0.60%)
ISIN
KR7009290008
Return %
Stock
S&P 500
1Y
14.41
14.39
3Y
-17.52
81.42
5Y
-16.37
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sung-Won Choi
- Full Time Employees
- 1,022
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Gasan Building Gwacheon-si GY South Korea 04632
- IPO Date
- Nov 17, 1989
- Website
- ekdp.com
- Similar Companies
- Business
- Kwang Dong Pharmaceutical Co., Ltd. (009290.KS) develops, manufactures, and markets over-the-counter (OTC) drugs, ethical drugs (ETC), health supplements, and functional beverages in South Korea. The company offers OTC products including ophthalmic solutions such as eye drops, mineral preparations, nutritious tonics, antipyretic and analgesic agents, anti-inflammatory drugs, circulatory system treatments, and vitamins; ETC drugs encompassing anti-malignant-tumor agents like Copolang, obesity treatments, appetite suppressants, neuropsychiatric solvents, digestive agents, antibiotics, and vitamins; supplements featuring low-content vitamins, minerals, and vital energy substances; and quasi-drugs alongside traditional health foods. Its prominent beverage portfolio includes Vita500 vitamin drink, Vita Gold, Red Ginseng Gold, blackberry drinks, ginger lonicerae flos beverages, corn silk tea, men's tea (oriental raisin tea), and consumer drinks such as SunKist orange soda, promoted through TV, radio, and print advertising; key OTC brands comprise Kwangdong Kyung Ok Go tonic, Kwangdong Woo Hwang Chong Shim Won stroke preparation, Kwangdong Ssangwha Tang, and eye care products like I-Talk eye drops. In the pipeline, the company advances therapies such as BST-204 for neoplasms, KD302 for neuralgia, KD103 for Alzheimer's disease, and others in preclinical stages. Kwang Dong Pharmaceutical operates primarily in the human healthcare sector, targeting consumers and healthcare professionals in South Korea with a focus on oriental medicine scientification, OTC remedies, prescription pharmaceuticals, and nutritional beverages. Founded in 1963 and headquartered at Gasan Building, 85 Seochojungang-ro, Seocho-gu, Seoul, South Korea, the company maintains about 1,032 employees and pursues R&D in cardiovascular, central nervous system, anti-infective, and ophthalmic areas. In September 2025, Kwang Dong Pharmaceutical entered an exclusive licensing agreement with Ocugen, Inc. for OCU400, a modifier gene therapy for retinitis pigmentosa (RP), securing rights in Korea with up to $7.5 million in upfront and milestone payments, potential $180 million in sales milestones over 10 years, and 25% royalties on net sales, while Ocugen handles manufacturing to bolster Kwangdong's ophthalmology portfolio alongside presbyopia and pediatric myopia pipelines. This strategic alliance enhances the company's position in advanced ophthalmic gene therapies, aiming to address approximately 7,000 RP patients in Korea pending regulatory approval. The partnership reflects Kwangdong's ongoing commitment to innovative R&D and global collaborations, building on prior achievements like the first Vitamin D injection in Korea (B.O.N.) and ERP system implementation for operational efficiency.